© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.
In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.
REPORT EXAMINES COST-EFFECTIVENESS OF DUPILUMAB FOR ATOPIC DERMATITIS: The biologic dupilumab is projected to be a cost-effective treatment for moderate-to-severe atopic dermatitis, shows a new study. (©Dzm1try/Shutterstock.com)
CLINICAL TRIALS REPORT: TRALOKINUMAB FOR ATOPIC DERMATITIS: Study shows that blocking IL-13 improves atopic dermatitis â a promising finding for IL-13 atopic dermatitis drugs in development. (©AnthonyRicci/Shutterstock.com)
GENETIC FACTORS UNIQUE TO ITCH: Mapping the human genome for chronic itch holds the potential to develop targeted therapy for atopic dermatitis and psoriasis itch, a study shows. (©PatrizioMartorana/Shutterstock.com)
IT MAY BE TIME FOR ACT TWO IN ATOPIC DERMATITIS RESEARCH: For some patients with moderate to severe atopic dermatitis, the combination of dupilumab and corticosteroids may be necessary to control flares, a new study shows. Dupilumab is a proven treatment for AD, so where do we go from here? A physician writing in BJD suggests predictive modeling. (©TYLim/Shutterstock.com)
BIOLOGIC CLEARS SEVERE DERMATITIS OF THE HANDS: Three patients achieve 80-100 percent clearance of moderate-to-severe dyshidrosis of the hands and palms after treatment with dupilumab. (©TernavskaialgaAlibec/Shutterstock.com)
ATOPIC DERMATITIS PRURITIS TRIAL FAILS: Symptomatic relief remains out of reach for many who suffer chronic pruritis. Without drugs specifically approved to treat chronic itch, providers and patients rely on therapies with limited efficacy. Here’s an update of two important clinical trials. (©DeepBlue/Shutterstock.com)
VITAMINS A AND D NOT BENEFICIAL IN ATOPIC DERMATITIS: Topical vitamin A provides no benefit in treating atopic dermatitis, whereas topical vitamin D may actually exacerbate symptoms, according to an evidence-based review. (©TernavskaialgaAlibec/Shutterstock.com)
DISEASE BURDEN HIGH FOR ADULTS TO ATOIC DERMATITIS: Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology. (©AnthonyRicci/Shutterstock.com)
HEART DISEASE RISK HIGH IN ATOPIC ECZEMA: Observational study shows high heart disease risk in severe and predominantly active atopic eczema. (©TheerapolPongkangsananan/Shutterstock.com)